Adaptive Biotechnologies Corporation is rated Hold as MRD segment momentum offset by competitive & valuation concerns. Read ...
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago. These ...
Even as education spending is projected to inch up two percent this year to reach $67.8 billion worldwide, the way in which school districts, colleges and universities are spending that money is ...
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.43 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.33 per share a year ago. These figures are ...
Even as education spending is projected to inch up two percent this year to reach $67.8 billion worldwide, the way in which school districts, colleges and universities are spending that money is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback